Program
cyclobenzaprine
Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.
Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonix Pharmaceuticals | 262 open or running | phase 3since Jul 12, 2013 | Dec 7, 2011 | Feb 2028phase 2 · NCT07621237 |
| Eurofarma Laboratorios | 10 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Johnson & Johnson | 10 open or running | phase 4since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Neurana Pharmaceuticals | 10 open or running | phase 1since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Novartis | 10 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| Takeda | 10 open or running | phase 3since Jun 23, 2016 | Jun 23, 2016 | none ahead |
Also a collaborator on its studies: altasciences-company-inc, premier-research-group-plc and cognitive-research-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Oct 28, 2005.
- Apr 25, 2017Phase 1 study in Healthy AdultsTonix Pharmaceuticals · NCT03168022 · 43 enrolled · Canada
- Nov 14, 2017Neurana Pharmaceuticals's first study: phase 1 study in Driving ImpairedNew to Neurana PharmaceuticalsNeurana Pharmaceuticals · NCT03353922 · 35 enrolled · United States
- Feb 6, 2018Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT03443960 · 60 enrolled · Canada
- Apr 12, 2018Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03508700 · 93 enrolled · United States
- Feb 12, 2019Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03841773 · 192 enrolled · United States
- Nov 13, 2019Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT04164719 · 16 enrolled · Canada
- Nov 20, 2019Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04172831 · 503 enrolled · United States
- Aug 7, 2020Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04508621 · 514 enrolled · United States
- Mar 1, 2022Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT05273749 · 457 enrolled · United States
- May 9, 2022Phase 2 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT05372887 · Kenya
- Jul 21, 2022Phase 2 study in InfectionsTonix Pharmaceuticals · NCT05472090 · 63 enrolled · United States
- Jan 26, 2026Phase 1 study in PharmakokineticTonix Pharmaceuticals · NCT07413367 · 50 enrolled · Canada
- Mar 6, 2026Phase 1 study in Healthy Subjects (HS)Tonix Pharmaceuticals · NCT07464535 · 20 enrolled · United States
- May 27, 2026Phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237 · 360 planned · United States
Ahead
- Feb 2028Primary completion: phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07621237Depressive Disorder, Major · United States | 2 | Recruiting | Tonix Pharmaceuticals | Feb 2028 | 360 |
| NCT07464535Healthy Subjects (HS) · United States | 1 | Completed | Tonix Pharmaceuticals | Apr 30, 2022 | 20 |
| NCT07413367Pharmakokinetic · Canada | 1 | Active, not recruiting | Tonix Pharmaceuticals | Feb 10, 2026 | 50 |
| NCT05472090Infections · United States | 2 | Completed | Tonix Pharmaceuticals | Jul 12, 2023 | 63 |
| NCT05372887Stress Disorders, Post-Traumatic · Kenya | 2 | Withdrawn | Tonix Pharmaceuticals | Nov 8, 2022 | 0 |
| NCT05273749Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Nov 14, 2023 | 457 |
| NCT04508621Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Nov 1, 2021 | 514 |
| NCT04172831Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Oct 29, 2020 | 503 |
| NCT04164719Healthy Subjects · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 24, 2019 | 16 |
| NCT03841773Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Apr 24, 2020 | 192 |
| NCT03508700Stress Disorders, Post-Traumatic · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 30, 2019 | 93 |
| NCT03443960Healthy Subjects · Canada | 1 | Completed | Tonix Pharmaceuticals | Apr 9, 2018 | 60 |
| NCT03353922Driving Impaired · United States | 1 | Completed | Neurana Pharmaceuticals | Dec 6, 2017 | 35 |
| NCT03168022Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Jan 26, 2016 | 43 |
| NCT03110575Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Jul 27, 2018 | 190 |
| NCT03062540Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Tonix Pharmaceuticals | Jul 27, 2018 | 358 |
| NCT02829814Fibromyalgia · United States | 3 | Terminated | Tonix Pharmaceuticals | Sep 13, 2016 | 51 |
| NCT02814565Neck Pain · Russian Federation | 3 | Completed | Takeda | Feb 10, 2017 | 180 |
| NCT02589275Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 28, 2016 | 375 |
| NCT02436096Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Sep 2016 | 519 |
| NCT02421679Stress Disorders, Post-Traumatic · United States | 2 | Completed | Tonix Pharmaceuticals | May 26, 2016 | 159 |
| NCT02277704Stress Disorders, Post-Traumatic · United States | 2 | Completed | Tonix Pharmaceuticals | May 2016 | 245 |
| NCT02015234Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Aug 2015 | 158 |
| NCT01903265Fibromyalgia · United States | 3 | Completed | Tonix Pharmaceuticals | Jul 2014 | 205 |
| NCT01889173Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 2013 | 24 |
| NCT01689259Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 2013 | 24 |
| NCT01634412Healthy Adults · Canada | 1 | Completed | Tonix Pharmaceuticals | Sep 2013 | 24 |
| NCT01587508Acute Lumbago · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | May 2013 | 0 |
| NCT01490788Healthy · Canada | 1 | Completed | Tonix Pharmaceuticals | Dec 30, 2011 | 30 |
| NCT00913419Depression | 1 | Completed | Novartis | Dec 1988 | 30 |
| NCT00778037Healthy · India | – | Completed | Sun Pharmaceutical Industries | Sep 2006 | 40 |
| NCT00246389Pain | 4 | Completed | Johnson & Johnson | 1,000 |
How it is read
Names in the registry
- “TNX-102 SL”, 13 entries
- “TNX-102 SL 5.6 mg”, 2 entries
- “Treatment A”, 2 entries
- “Treatment B”, 2 entries
- “TNX-102 SL Tablet”, 1 entry
Codes read as this program: TNX102.
Conditions, from the studies’ own filings
- Fibromyalgia, 8 studies
- Stress Disorders, Post-Traumatic, 7 studies
- Depressive Disorder, Major, 1 study
- Post-Acute COVID-19 Syndrome, 1 study
- Neck Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.